A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Vatalanib (Primary)
  • Indications Malignant melanoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 02 Aug 2011 Planned end date changed from 1 Dec 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top